Drugs and mitochondrial diseases: 40 queries and answers

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 527-543

  Mancuso, Michelangelo ^a   Orsucci, Daniele ^a   Filosto, Massimiliano ^b   Simoncini, Costanza ^a   Siciliano, Gabriele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Carnitine; Coenzyme Q10; Creatine; Mitochondria; Mitochondrial diseases; MtDNA; Riboflavin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ALPHA TOCOPHEROL; AMINOGLYCOSIDE; ARGININE; BENZOQUINONE DERIVATIVE; BETA CAROTENE; BEZAFIBRATE; CARNITINE; CREATINE; DICHLOROACETIC ACID; DIDANOSINE; DIMETHYLGLYCINE; EPI 743; ETIRACETAM; GREEN TEA EXTRACT; IDEBENONE; LINEZOLID; MAGNESIUM; METFORMIN; METOPROLOL; PHENYTOIN; PYRUVIC ACID; RETINOL; RIBOFLAVIN; SIMVASTATIN; TETRACYCLINE; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANTICONVULSANT THERAPY; CARNITINE DEFICIENCY; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CYCLOOXYGENASE DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; ENZYME DEFICIENCY; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; FRIEDREICH ATAXIA; GENE MUTATION; HEARING IMPAIRMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE PSEUDOOBSTRUCTION; INTRACTABLE EPILEPSY; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; MELAS SYNDROME; MITOCHONDRIAL DNA DEPLETION SYNDROME; MYOCLONUS EPILEPSY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; VISUAL ACUITY;

ACIDOSIS, LACTIC; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MITOCHONDRIAL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857298896     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.657177     Document Type: Review

References (139)

1. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656-68 (Pubitemid 36741594)
2. Filosto M, Mancuso M. Mitochondrial diseases: a nosological update. Acta Neurol Scand 2007;115:211-21 (Pubitemid 46449589)
3. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008;63:35-9 (Pubitemid 351240549)
4. Khan SM, Smigrodzki RM, Swerdlow RH. Cell and animal models of mtDNA biology: progress and prospects. Am J Physiol Cell Physiol 2007;292:C658-69
5. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-3 (Pubitemid 19273941)
6. Couplan E, Aiyar RS, Kucharczyk R, et al. A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA 2011;108:11989-94
7. Kawamata H, Tiranti V, Magrane J, et al. adPEO mutations in ANT1 impair ADP-ATP translocation in muscle mitochondria. Hum Mol Genet 2011;20:2964-74
8. Fulop L, Szanda G, Enyedi B, et al. The effect of OPA1 on mitochondrial Ca(2) signaling. PLoS ONE 2011;6:e25199
9. Longley MJ, Graziewicz MA, Bienstock RJ, Copeland WC. Consequences of mutations in human DNA polymerase gamma. Gene 2005;354:125-31 (Pubitemid 41116691)
10. Li FY, Cuddon PA, Song J, et al. Canine spongiform leukoencephalomyelopathy is associated with a missense mutation in cytochrome b. Neurobiol Dis 2006;21:35-42 (Pubitemid 41817303)
11. Nakada K, Hayashi J. Transmitochondrial mice as models for mitochondrial DNA-based diseases. Exp Anim 2011;60:421-31
12. Viscomi C, Burlina AB, Dweikat I, et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 2010;16:869-71
13. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;CD004426
14. Koga Y, Povalko N, Katayama K, et al. Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev 2012;34:87-91
15. Saito K, Kimura N, Oda N, et al. Pyruvate therapy for mitochondrial DNA depletion syndrome. Biochim Biophys Acta 2011
16. Orsucci D, Filosto M, Siciliano G, Mancuso M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev 2009;67:427-38
17. Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med 2000;29:285-94
18. Sacconi S, Trevisson E, Salviati L, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010;20:44-8
19. Cotan D, Cordero MD, Garrido-Maraver J, et al. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 2011;25:2669-87
20. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-18
21. Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42:739-48
22. Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion 2007;7(Suppl):S72-7
23. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40:445-53
24. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician 2005;72:1065-70 (Pubitemid 43093261)
25. Land JM, Heales SJ, Duncan AJ, Hargreaves IP. Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency. Neurochem Res 2007;32:837-43 (Pubitemid 46481312)
26. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ. Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 2010;19:535-54
27. DiMauro S, Quinzii CM, Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 2007;117:587-9 (Pubitemid 46348513)
28. Quinzii CM, Lopez LC, Naini A, et al. Human CoQ10 deficiencies. Biofactors 2008;32:113-18
29. Lopez LC, Quinzii CM, Area E, et al. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS ONE 2010;5:e11897
30. Di Prospero NA, Sumner CJ, Penzak SR, et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8 (Pubitemid 46919834)
31. Orsucci D, Mancuso M, Ienco EC, et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme q10 and its analogues. Curr Med Chem 2011;18:4053-64
32. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134:2677-86
33. Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011;134:e188
34. Esposti MD, Ngo A, Ghelli A, et al. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 1996;330:395-400 (Pubitemid 26172376)
35. Giorgio V, Petronilli V, Ghelli A, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta 2012;1817:363-9
36. Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012;105:91-102
37. Beg S, Javed S, Kohli K. Bioavailability enhancement of coenzyme Q10: an extensive review of patents. Recent Pat Drug Deliv Formul 2010;4:245-55
38. Fetoni AR, Piacentini R, Fiorita A, et al. Water-soluble Coenzyme Q10 formulation (Q-ter) promotes outer hair cell survival in a guinea pig model of noise induced hearing loss (NIHL). Brain Res 2009;1257:108-16
39. Cocheme HM, Kelso GF, James AM, et al. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 2007;7(Suppl):S94-102
40. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005;280:21295-312 (Pubitemid 40805692)
41. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007;581:431-44 (Pubitemid 46831747)
42. Ohnishi S, Okamura N, Sakamoto S, et al. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet 2008;23:293-303
43. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999;21:91-4 (Pubitemid 29036290)
44. Paddon-Jones D, Borsheim E, Wolfe RR. Potential ergogenic effects of arginine and creatine supplementation. J Nutr 2004;134: 2888S-94S.discussion 95S (Pubitemid 39315242)
45. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-9 (Pubitemid 27512338)
46. Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000;55:1748-51
47. Burke DG, Chilibeck PD, Parise G, et al. Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab 2003;13:294-302 (Pubitemid 37108362)
48. Mayr JA, Zimmermann FA, Fauth C, et al. Lipoic Acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am J Hum Genet 2011;89:792-7
49. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995;242:472-7
50. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35:235-42
51. Bugiani M, Lamantea E, Invernizzi F, et al. Effects of riboflavin in children with complex II deficiency. Brain Dev 2006;28:576-81 (Pubitemid 44293175)
52. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007;130:2037-44 (Pubitemid 47236610)
53. Gerards M, van den Bosch BJ, Danhauser K, et al. Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain 2011;134:210-19
54. Lee DW, Selamoglu N, Lanciano P, et al. Loss of a conserved tyrosine residue of cytochrome b induces reactive oxygen species production by cytochrome BC1. J Biol Chem 2011;286:18139-48
55. Vives-Bauza C, Gonzalo R, Manfredi G, et al. Enhanced ROS production and antioxidant defenses in cybrids harbouring mutations in mtDNA. Neurosci Lett 2006;391:136-41 (Pubitemid 41736187)
56. Hargreaves IP, Sheena Y, Land JM, Heales SJ. Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis 2005;28:81-8 (Pubitemid 40253986)
57. Vergani L, Malena A, Sabatelli P, et al. Cultured muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants. Brain 2007;130:2715-24 (Pubitemid 47511702)
58. Atkuri KR, Cowan TM, Kwan T, et al. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci USA 2009;106:3941-5
59. Mancuso M, Orsucci D, Logerfo A, et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 2010;257:774-81
60. Barbieri E, Sestili P. Reactive oxygen species in skeletal muscle signaling. J Signal Transduct 2012;2012:982794
61. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842-57 (Pubitemid 46333949)
62. Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res 2000;33:329-40
63. Soni MG, Thurmond TS, Miller ER III, et al. Safety of vitamins and minerals: controversies and perspective. Toxicol Sci 2010;118:348-55
64. De Stefano N, Matthews PM, Ford B, et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45:1193-8
65. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30 (Pubitemid 43739931)
66. Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003;142:62-6 (Pubitemid 36106391)
67. Yoneda M, Ikawa M, Arakawa K, et al. In vivo functional brain imaging and a therapeutic trial of l-arginine in MELAS patients. Biochim Biophys Acta 2011
68. Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006;66:1766-9 (Pubitemid 43964643)
69. Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005;64:710-12 (Pubitemid 40261903)
70. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010;99:246-55
71. Koene S, Smeitink J. Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction. J Inherit Metab Dis 2011;34:315-25
72. Ioannou N, Hargreaves IP, Allen G, et al. Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: implications for mitochondrial cytopathies and neurodegenerative diseases. Biofactors 2010;36:468-73
73. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/ PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008;8:249-56
74. Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 2012;21:526-35
75. Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab 2011;14:80-90
76. Golubitzky A, Dan P, Weissman S, et al. Screening for Active Small Molecules in Mitochondrial Complex I Deficient Patient's Fibroblasts, Reveals AICAR as the Most Beneficial Compound. PLoS ONE 2011;6:e26883
77. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 2004;37:304-17 (Pubitemid 38833997)
78. Orsucci D, Calsolaro V, Mancuso M, Siciliano G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009;8:222-31
79. Haroon MF, Fatima A, Scholer S, et al. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol Dis 2007;28:237-50 (Pubitemid 350116596)
80. Omar A, Johnson LN. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. Neurology 2007;68:1159-60 (Pubitemid 46559856)
81. Mancuso M, Orsucci D, Calsolaro V, et al. Tetracycline treatment in patients with progressive external ophthalmoplegia. Acta Neurol Scand 2011;124:417-23
82. Giordano C, Montopoli M, Perli E, et al. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain 2011;134:220-34
83. Voet NB, van der Kooi EL, Riphagen II, et al. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2010;CD003907
84. Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 2010;19:1974-84
85. DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 2007;27:125-37 (Pubitemid 46940941)
86. Tachibana M, Sparman M, Sritanaudomchai H, et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009;461:367-72
87. Finsterer J. Treatment of central nervous system manifestations in mitochondrial disorders. Eur J Neurol 2011;18:28-38
88. Finsterer J. Management of mitochondrial stroke-like-episodes. Eur J Neurol 2009;16:1178-84
89. Rossi FH, Okun M, Yachnis A, et al. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002;8:313-15
90. Visser NA, Braun KP, Leijten FS, et al. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011;258:218-22
91. Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010;33:138-51
92. Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006;243:97-9
93. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006;47:469-78 (Pubitemid 43351547)
94. Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129:1685-92 (Pubitemid 43999403)
95. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007;22:105-9 (Pubitemid 46354826)
96. Chiyonobu T, Noda R, Yoshida M, et al. Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 2008;30:430-3
97. Aldakkak M, Stowe DF, Chen Q, et al. Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release. Cardiovasc Res 2008;77:406-15 (Pubitemid 351197651)
98. Araujo IM, Ambrosio AF, Leal EC, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004;45:1498-505 (Pubitemid 39648274)
99. Costa C, Belcastro V, Tozzi A, et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 2008;28:8040-52
100. Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21:297-302
101. Belotti EA, Taddeo I, Ragazzi M, et al. Chronic impact of topiramate on acid-base balance and potassium in childhood. Eur J Paediatr Neurol 2010;14:445-8
102. Shiber JR. Severe non-anion gap metabolic acidosis induced by topiramate: a case report. J Emerg Med 2010;38:494-6
103. Lu J, Li Z, Zhu Y, et al. Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion 2010;10:380-90
104. Rydzanicz M, Wrobel M, Pollak A, et al. Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochem Biophys Res Commun 2010;395:116-21
105. Qian Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 2009;53:4612-18
106. Hobbie SN, Akshay S, Kalapala SK, et al. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008;105:20888-93
107. Cope TE, McFarland R, Schaefer A. Rapid-onset, linezolid-induced lactic acidosis in MELAS. Mitochondrion 2011;11:992-3
108. Zoraster RM, Rison RA. Severe lactic acidosis secondary to minocycline in a teenager with infectious mononucleosis and mitochondrial myopathy. Clin Neurol Neurosurg 2008;110:627-30
109. Kupsch K, Hertel S, Kreutzmann P, et al. Impairment of mitochondrial function by minocycline. FEBS J 2009;276:1729-38
110. Jones CN, Miller C, Tenenbaum A, et al. Antibiotic effects on mitochondrial translation and in patients with mitochondrial translational defects. Mitochondrion 2009;9:429-37
111. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70
112. Protti A, Russo R, Tagliabue P, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care 2010;14:R22
113. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7 (Pubitemid 46856819)
114. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62:1709-12 (Pubitemid 41626667)
115. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60-8 (Pubitemid 40956932)
116. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81:650-3 (Pubitemid 46625111)
117. Tay SK, Dimauro S, Pang AY, et al. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol 2008;39:426-8
118. Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol 2009;107:8-16
119. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003;27:142-56 (Pubitemid 36169325)
120. Pfeffer G, Cote HC, Montaner JS, et al. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009;73:71-2
121. Mastaglia FL, Needham M. Update on Toxic Myopathies. Curr Neurol Neurosci Rep 2012;12:54-61
122. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-6
123. Muravchick S. Clinical implications of mitochondrial disease. Adv Drug Deliv Rev 2008;60:1553-60
124. Hanley PJ, Ray J, Brandt U, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 2002;544:687-93 (Pubitemid 35355950)
125. Vanlander AV, Jorens PG, Smet J, et al. Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome. Acta Anaesthesiol Scand 2012
126. Morgan PG, Hoppel CL, Sedensky MM. Mitochondrial defects and anesthetic sensitivity. Anesthesiology 2002;96:1268-70 (Pubitemid 34462594)
127. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011;107:48-56
128. Parikh S, Saneto R, Falk MJ, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009;11:414-30
129. Battaglia V, Salvi M, Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J Biol Chem 2005;280:33864-72 (Pubitemid 41443106)
130. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005;42:110-16 (Pubitemid 40038908)
131. Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br J Clin Pharmacol 2011;71:20-8
132. Maharaj H, Maharaj DS, Daya S. Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. Life Sci 2006;78:2438-43
133. Hadzimichalis NM, Baliga SS, Golfetti R, et al. Acetaminophen-mediated cardioprotection via inhibition of the mitochondrial permeability transition pore-induced apoptotic pathway. Am J Physiol Heart Circ Physiol 2007;293:H3348-55 (Pubitemid 350230875)
134. Baliga SS, Jaques-Robinson KM, Hadzimichalis NM, et al. Acetaminophen reduces mitochondrial dysfunction during early cerebral postischemic reperfusion in rats. Brain Res 2010;1319:142-54
135. Cordero MD, Moreno-Fernandez AM, Gomez-Skarmeta JL, et al. Coenzyme Q10 and alpha-tocopherol protect against amitriptyline toxicity. Toxicol Appl Pharmacol 2009;235:329-37
136. Moreno-Fernandez AM, Cordero MD, Garrido-Maraver J, et al. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res 2011
137. Morris CG, Low J. Metabolic acidosis in the critically ill: part 2. Causes and treatment. Anaesthesia 2008;63:396-411 (Pubitemid 351365030)
138. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010;6:274-85
139. Mancuso M, Orsucci D, Calsolaro V, et al. Coenzyme Q10 and Neurological Diseases. Pharmaceuticals 2009;2:134-49